证券代码：002390 证券简称：信邦制药 公告编号：2023-020 出席本次活动人员：董事长安吉女士，独立董事邱刚先生，副 总经理、财务总监肖娅筠女士，副总经理、董事会秘书陈船女士。 参 与 方 式 ： 投 资 者 可 于 业 绩 说 明 会 召 开 时 间 登 录 http://rs.p5w.net 进入专区页面参与交流。 二、投资者问题提前征集 贵州信邦制药股份有限公司 关于参加2022年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年 度报告》，为加强与投资者的交流互动，便于投资者进一步了解公 司 2022 年度经营情况及其他关切问题，公司将参加在贵州证监局指 导下，贵州证券业协会联合深圳市全景网络有限公司举办的"2022 年度贵州辖区上市公司业绩说明会暨投资者集体接待日活动"，具 体安排如下： 一、业绩说明会的安排 召开时间：2023 年 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,605,127,137.43, representing a 1.70% increase compared to ¥1,578,346,374.84 in the same period last year[2] - Net profit attributable to shareholders decreased by 27.94% to ¥52,944,770.89 from ¥73,477,230.21 year-on-year[2] - Net profit for Q1 2023 was CNY 62,648,520.70, a decrease from CNY 79,535,695.47 in Q1 2022, reflecting a decline of approximately 21.2%[16] - The total comprehensive income for Q1 2023 was ¥62,648,520.70, down from ¥79,535,695.47 in the same period last year, reflecting a decline of approximately 21%[17] - The basic and diluted earnings per share for Q1 2023 were both ¥0.03, compared to ¥0.04 in Q1 2022, indicating a 25% decrease[17] Cash Flow - The net cash flow from operating activities significantly dropped by 98.40%, amounting to ¥2,178,740.78 compared to ¥136,064,884.82 in the previous year[5] - Cash received from sales of goods and services in Q1 2023 was ¥1,465,643,505.99, a decline of about 7.4% from ¥1,582,853,471.06 in Q1 2022[20] - The net cash flow from operating activities for Q1 2023 was ¥2,178,740.78, significantly lower than ¥136,064,884.82 in Q1 2022[20] - The net cash flow from investing activities in Q1 2023 was -¥48,209,725.41, compared to -¥72,216,888.53 in Q1 2022, showing an improvement in cash outflow[21] - The net cash flow from financing activities for Q1 2023 was ¥60,850,727.62, contrasting with a negative cash flow of -¥9,290,728.22 in Q1 2022[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,889,925,341.80, a 0.99% increase from ¥9,793,091,573.35 at the end of the previous year[2] - Total assets as of March 31, 2023, amounted to CNY 9,889,925,341.80, compared to CNY 9,793,091,573.35 at the beginning of the year, showing an increase of about 1.0%[12] - Total liabilities as of March 31, 2023, were CNY 2,763,288,937.98, slightly up from CNY 2,728,042,922.48 at the start of the year, representing an increase of approximately 1.3%[13] Shareholder Information - The total equity attributable to shareholders increased by 0.78% to ¥6,861,396,417.39 from ¥6,808,451,646.50 at the end of the previous year[2] - The company had a total of 82,166 common shareholders at the end of the reporting period[7] - The company's total equity as of March 31, 2023, was CNY 7,126,636,403.82, compared to CNY 7,065,048,650.87 at the beginning of the year, reflecting a growth of about 0.9%[13] Research and Development - Research and development expenses surged by 398.74% to ¥691,393.55, indicating increased investment in R&D projects[5] - Research and development expenses for Q1 2023 were CNY 691,393.55, significantly higher than CNY 138,626.92 in Q1 2022, marking an increase of approximately 397.5%[16] Other Income - The company reported a significant increase in other operating income, which rose by 447.32% to ¥1,217,905.71 compared to ¥222,522.05 in the previous year[5] Equity and Returns - The weighted average return on equity decreased by 0.33 percentage points to 0.77% from 1.10% year-on-year[2]

Business Focus and Structure - The company reported a significant change in its main business focus from pharmaceutical manufacturing to medical services, pharmaceutical distribution, and pharmaceutical manufacturing since March 2014[32]. - The company’s major shareholder has changed from Zhang Guanfeng to Harbin Yuxi Venture Capital Co., Ltd. in August 2017, and then to Guizhou Jinyu Industrial Investment Partnership (Limited Partnership) in June 2021[32]. - The company has established multiple subsidiaries, including Guizhou Kexin Pharmaceutical Co., Ltd. and Guizhou Tongde Pharmaceutical Co., Ltd., enhancing its market presence[13]. - The company operates seven medical institutions, including the only Grade A tumor specialty hospital in Guizhou Province[47]. - The company has established a comprehensive healthcare industry chain, integrating medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing[51]. Financial Performance - The financial report for the year 2022 was confirmed to be true, accurate, and complete by the responsible persons including the company leader and accounting supervisor[2]. - The annual report includes a comprehensive analysis of the company's financial indicators, which are crucial for assessing performance[29]. - The company's operating revenue for 2022 was ¥6,350,025,827.03, a decrease of 1.88% compared to ¥6,471,866,334.96 in 2021[34]. - The net profit attributable to shareholders for 2022 was ¥224,479,086.87, down 17.73% from ¥272,869,187.71 in 2021[34]. - The net cash flow from operating activities increased by 29.00% to ¥590,796,585.74 in 2022, compared to ¥457,971,988.24 in 2021[34]. - Basic and diluted earnings per share for 2022 were both ¥0.12, representing a decrease of 20.00% from ¥0.15 in 2021[35]. - The weighted average return on equity for 2022 was 3.36%, down 1.37 percentage points from 4.73% in 2021[35]. - Total assets at the end of 2022 were ¥9,793,091,573.35, an increase of 1.71% from ¥9,628,645,372.98 at the end of 2021[35]. - Net assets attributable to shareholders at the end of 2022 were ¥6,808,451,646.50, up 2.85% from ¥6,619,762,004.21 at the end of 2021[35]. Market Trends and Opportunities - The pharmaceutical distribution market in China continues to grow, driven by increasing healthcare demands and improved medical insurance systems[48]. - The aging population in China is expected to drive increased demand for healthcare services and pharmaceutical products, presenting growth opportunities for the company[66]. - The overall healthcare expenditure in China reached CNY 7.56 trillion in 2021, accounting for 6.58% of GDP, indicating a growing market for pharmaceutical products[64]. - The company aims to expand its market presence by leveraging its strengths in product development and distribution channels[64]. - The company is exploring digital transformation and innovative service models to improve supply chain logistics and customer service[70]. Revenue Breakdown - Revenue from pharmaceutical distribution was ¥5,280,248,211.04, accounting for 66.51% of total revenue, down 1.53% from the previous year[95]. - Revenue from medical services decreased by 10.18% to ¥1,860,172,021.49, representing 23.43% of total revenue[95]. - Pharmaceutical manufacturing revenue increased by 12.23% to ¥790,255,875.26, making up 9.95% of total revenue[95]. - The total operating revenue for the company in Q4 2022 was approximately CNY 1.66 billion, showing a slight increase compared to previous quarters[60]. Operational Efficiency and Management - The company has implemented a centralized management model to enhance resource sharing and operational efficiency across its medical services[76]. - The company has established a platform operating model that integrates medical services, pharmaceutical distribution, and manufacturing, enhancing its competitive edge[82]. - The company is focusing on expanding its medical services to address the growing demand for healthcare resources in underserved areas[97]. - The company has developed a modern pharmaceutical logistics distribution system that not only supports its own operations but also provides third-party logistics services[117]. Research and Development - The company has been focusing on the development of new products and technologies to enhance its market position in the pharmaceutical industry[64]. - The company aims to enhance the quality of traditional Chinese medicine (TCM) and has established a comprehensive quality control system for TCM materials[73]. - The company has received approval for over 40 research projects in 2022, including 1 national-level project and 31 provincial-level projects[140]. - The company is focusing on research related to cancer treatment, particularly in improving chemotherapy resistance in pancreatic cancer[173]. Challenges and Risks - The company faces risks related to rising costs, including raw material prices and labor costs, which may impact future profitability[200]. - The company is exposed to financial risks due to its extensive operations in medical services and pharmaceutical distribution, requiring significant working capital[200]. - The company is adapting to industry changes driven by policies such as "two-invoice system" and "volume-based procurement," which are reshaping the pharmaceutical landscape[80]. Strategic Initiatives - The company aims to build a high-tech medical service group, focusing on medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing[199]. - The company is pursuing both organic growth and strategic acquisitions to ensure sustainable and stable development, creating more value for shareholders[119]. - The company has initiated several projects under its five-year technology innovation plan, including the application for 8 invention patents and 1 utility model patent[141].

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-09-23 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 中国银河证券股份有限公司：全铭 | | 人员姓名 | | 易方达基金管理有限公司：王俊杰 | | | | 华润元大基金管理有限公司：张磊 | | | | 北京亚宝投资管理有限公司：郭常平 | | | 深圳尊道投资有限公司：张伟生 | | | | | 广东小禹投资管理有限公司：何结领 | | | | 北京亚宝投资管理有限公司：郭常平 | | | 东莞证券股份有限公司 | : 陈毅 | | | | 上海之上资产管理有限公司：周坤 | | ...

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-07-22 | --- | --- | --- | |----------------|------------------------------------|--------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 中国国际金融股份有限公司: 兰兰 | | | 人员姓名 | 汇添富基金管理股份有限公司: 刘江 | | | 时间 | 2015 年 7 月 22 日 | 10:00-12:00 | | 地点 | 公司总部五楼会议室 | | | 上市公司接待人 | 董事、总经理 安怀略 | | | 员姓名 | 董事、常务副总经理 孔令忠 | | | | 副总经理、董事会秘书 陈 船 | | | 投资者关系活动 | 一、签署《承诺书》 | | | 主要内容介绍 | | | | ...

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-11-11 | --- | --- | --- | |----------------|--------------------------------|------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 苏州智银投资咨询有限公司：袁岑 | | | 人员姓名 | 东吴证券股份有限公司：桑月 | | | | 华安基金管理有限公司：袁银泉 | | | 时间 | 2015 年 11 月 11 | 日 10:00-11:30 | | 地点 | | 贵州信邦制药股份有限公司董秘办公室 | | 上市公司接待人 | 董事会秘书 陈船 | | | 员姓名 | | | | 投资者关系活动 | 一、签署《承诺书》 | | | 主要内容介绍 | 二、投 ...

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2014-11-10 | --- | --- | --- | |----------------|---------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 复华证券投资信托：谢良武；富兰克林华美证券柚子信托：刘尹 | | 人员姓名 | 璇； | | | | | 国泰综合证券：古明宜、黄議瑲；上海理成资产管理：毛峥嵘； | | | | 野村证券投资信托：朱继元；统一证券投资信托：陈意婷、林子 | | | 钦； | | | | | 保德信证券投资信托：杨国昌； 盈喜投资管理：刘世平； | | | | 国金证券：郭妮妮； 国泰证券投资信托：温瑞 ...

证券简称：信邦制药 证券代码：002390 证券代码：002390 证券简称：信邦制药 贵州信邦制药股份股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |-----------------------------|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 ...

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-08-29 | --- | --- | --- | |----------------|--------------------------------------|----------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 海通证券股份有限公司：师成平、廖庆阳 | | | 人员姓名 | 中海基金管理有限公司 | : 郑辰 | | | | | | | 摩根士丹利华基金管理有限公司 | : 缪东航 | | | 上投摩根基金管理有限公司:罗会礼 | | | | 申万菱信基金管理有限公司：杨扬 | | | 时间 | 2015 年 8 月 29 | 日 10:00-11:30 | | 地点 | 公司总部五楼会议室 | | | 上市公司接待人 | 副总经理、董事会秘书 陈 船 | ...